SYNTap

This biomarker test detects misfolded Synuclein, a prion-protein driving Parkinson’s, LBD, and other dementias, decades before symptoms appear. 

SYNTap-CSF Test

Using cerebral spinal fluid (CSF), this biomarker test helps doctors diagnose certain cognitive and motor disorders. Based on the accurate diagnosis, physicians can better direct treatments targeting Synuclein misfolded protein, including: 

Diagnosing Parkinson’s:

  1. People who show early signs of a motor disorder want to know with certainty whether they have a progressive Parkinson’s diagnosis.
  2. People in the high-risk category for Parkinson’s, including family history, previous head injuries or traumas, environmental risks, and want to know if they carry biomarkers indicating pre-symptomatic disease.

Diagnosing Alzheimer’s Versus LBD In Early Stages

Patients with early Alzheimer’s-like symptoms could fall into either Alzheimer’s or Lewy Body Dementia category.

  • A positive SYNTap-CSF test indicates an LBD diagnosis.
  • A negative SYNTap-CSF test in early dementia patients would trigger a more complex diagnostic protocol for Alzheimer’s.

Determining Proper Drug Treatment For Late-Stage Alzheimer’s Patients 

  1. Advanced Alzheimer’s patients often develop motor symptoms years after the initial diagnosis. Through our SYNTap test, if misfolded Synuclein is detected, the patient will likely respond well to Parkinson’s medications to treat the motor symptoms.
  2. Research shows about 60% of Alzheimer’s patients have misfolded Synuclein at very late stages. The SYNTap test will help doctors determine the appropriate use of Synuclein-targeted drugs for patients with advanced Alzheimer’s.

Our SYNTap test helps physicians accurately identify whether the patient has Alzheimer’s or Lewy Body Dementia (LBD) when cognitive changes first appear. Before SYNTap, this differential diagnosis was frequently prolonged, complicated, and expensive.

An accurate diagnosis to distinguish Alzheimer’s versus LBD is critical for patients since both diseases show similar early symptoms.

Misdiagnosing Alzheimer’s or LBD leads to severe consequences as both diseases require different drug treatments.

Drugs that work for LBD patients, for instance, can be harmful to Alzheimer’s patients, and vice versa. The SYNTap biomarker test ensures accuracy.

Alzheimer's Drug Development Funds Hero Image

An accurate diagnosis to distinguish Alzheimer’s versus LBD is critical for patients since both diseases show similar early symptoms.

Misdiagnosing Alzheimer’s or LBD leads to severe consequences as both diseases require different drug treatments.

Drugs that work for LBD patients, for instance, can be harmful to Alzheimer’s patients, and vice versa. The SYNTap biomarker test ensures accuracy.

GET EARLY DETECTION TESTING!

Complete the short form below to get notifications on early testing availability for Alzheimer’s, Parkinson’s, and Lewy Body Dementia.

Discover the benefits of early screening for brain health. 🔬Early detection empowers preventive care. Join us in the race to the cure! 💪❤️

The FDA awarded Amprion Breakthrough Device Designation for detecting the biomarker, Synuclein, a misfolded protein driving Parkinson’s, Lewy Body Dementia and other brain diseases.

Our one-of-a-kind biomarker test, SYNTap-CSF, enables doctors to accurately diagnose elusive neurodegenerative diseases such as Parkinson’s, Lewy Body Dementia and effectively differentiate Alzheimer’s related conditions.

Don't count the days, make the days count.
Muhammad Ali
Muhammad Ali